Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
ASX:IMR
Want to see AU:IMR full AI Analyst Report?
Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$1.50
â–¼(-8.54% Downside)
Action:Reiterated
Date:02/27/26
The score is held down primarily by weak financial performance: collapsing revenue, negative gross profit, large losses, and significant ongoing cash burn alongside elevated debt. Technicals are comparatively supportive (price above major moving averages with neutral-to-positive momentum), but valuation is constrained by ongoing unprofitability and no dividend yield data.
Positive Factors
Differentiated MRI-compatible Technology
Imricor's focus on MRI-compatible EP systems targets a structural shift away from X-ray fluoroscopy toward MRI-guided ablation. This specialized technology creates higher clinical barriers to entry, potential procedural advantages, and a durable niche that supports long-term product differentiation and pricing power.
Negative Factors
Collapsing Revenue & Negative Gross Profit
Severe revenue decline and persistently negative gross profit point to weak product uptake and poor unit economics. This structural revenue shortfall undermines operating leverage and means scaling will require both demand restoration and improvements to product margins to achieve sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated MRI-compatible Technology
Imricor's focus on MRI-compatible EP systems targets a structural shift away from X-ray fluoroscopy toward MRI-guided ablation. This specialized technology creates higher clinical barriers to entry, potential procedural advantages, and a durable niche that supports long-term product differentiation and pricing power.
Read all positive factors
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$558.45M
Dividend YieldN/A
Average Volume (3M)287.54K
Price to Earnings (P/E)―
Beta (1Y)2.02
Revenue Growth-68.64%
EPS Growth36.40%
CountryAU
Employees78
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding320,947,020
10 Day Avg. Volume240,875
30 Day Avg. Volume287,535
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.78Price Target Upside69.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$3.42M
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Company Description
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal prod...
How the Company Makes Money
null...
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 302.50K | 959.42K | 615.57K | 816.01K | 696.27K |
| Gross Profit | -2.10M | -924.12K | -1.12M | -1.53M | -1.90M |
| EBITDA | -22.56M | -15.55M | -21.87M | -16.47M | -19.57M |
| Net Income | -26.20M | -29.69M | -22.63M | -17.53M | -20.56M |
Balance Sheet | |||||
| Total Assets | 45.79M | 21.62M | 8.31M | 13.70M | 26.86M |
| Cash, Cash Equivalents and Short-Term Investments | 40.81M | 15.71M | 831.52K | 5.69M | 18.52M |
| Total Debt | 26.62M | 21.35M | 10.42M | 4.45M | 1.74M |
| Total Liabilities | 34.26M | 29.00M | 17.06M | 6.19M | 4.46M |
| Stockholders Equity | 11.53M | -7.38M | -12.83M | 7.51M | 22.40M |
Cash Flow | |||||
| Free Cash Flow | -20.20M | -15.65M | -13.06M | -17.06M | -18.11M |
| Operating Cash Flow | -19.75M | -15.57M | -12.98M | -16.82M | -17.49M |
| Investing Cash Flow | -22.47M | -74.98K | -82.78K | -238.86K | -695.30K |
| Financing Cash Flow | 44.55M | 30.33M | 8.21M | 3.94M | 11.59M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Negative
1.64
Price Trends
1.88
Negative
1.93
Negative
1.69
Positive
Market Momentum
-0.04
Negative
40.06
Neutral
36.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.88, and below the 200-day MA of 1.69, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.06 is Neutral, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IMR.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$558.45M | -20.72 | -109.63% | ― | -68.64% | 36.40% | |
45 Neutral | AU$16.38M | -0.58 | -165.13% | ― | 23.30% | -14.29% | |
44 Neutral | AU$48.61M | -11.56 | -417.72% | ― | -19.47% | 62.28% | |
44 Neutral | AU$79.42M | -4.02 | -54.48% | ― | 17.24% | -20.00% | |
44 Neutral | AU$152.45M | -14.33 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$30.63M | -2.38 | -180.06% | ― | 74.74% | 4.32% |
* Healthcare Sector Average
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
1.74
0.08
4.82%
AU:IPD
Impedimed Limited
0.01
-0.02
-56.25%
AU:HMD
HeraMED Ltd.
0.04
0.03
281.82%
AU:CYC
Cyclopharm Limited
0.63
-0.42
-40.00%
AU:MX1
Micro-X Ltd.
0.04
>-0.01
-16.00%
AU:EMV
EMvision Medical Devices Ltd.
1.64
-0.14
-7.87%
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Wins ASX Waiver as U.S. Reporting Status Takes Effect
May 26, 2026
Imricor Medical Systems, Inc., a U.S.-based medical technology firm listed on the ASX, now reports as a U.S. public company under the Securities Exchange Act of 1934. The company must file annual reports on Form 10-K and quarterly reports on Form ...
Imricor Options Lapse, Trimming Potential Future Dilution
May 21, 2026
Imricor Medical Systems has notified the market that 30,000 IMRAJ options, which were exercisable at various prices and expiring on various dates, have lapsed unexercised as of 13 May 2026. The expiry of these options, disclosed in an Appendix 3H ...
Imricor Corrects Executive Equity Allotment in ASX Filing
May 21, 2026
Imricor Medical Systems, Inc. has updated its disclosure to correct a typographical error in the reported number of unquoted securities issued to key management personnel. The company clarified that executive Jonathon Gut received 231,656 securiti...
Imricor Shareholders Back Board, Incentive Plan at 2026 Meeting
May 8, 2026
Imricor Medical Systems reported that all resolutions put to its 2026 Annual Stockholders Meeting were passed by poll, underscoring strong shareholder support for the company’s governance and incentive structures. Shareholders elected Class ...
Imricor Raises Capital via Institutional CDI Placement and Issues Cleansing Notice
May 8, 2026
Imricor Medical Systems has completed an institutional placement, issuing 32,432,433 CHESS Depositary Interests at A$1.85 each to sophisticated and institutional investors, with the new securities ranking equally with existing CDIs. The company ha...
Imricor Seeks ASX Quotation for Over 32 Million New CDIs
May 8, 2026
Imricor Medical Systems Inc., a medical technology firm specializing in MRI-compatible cardiac ablation solutions for the electrophysiology market, continues to expand its presence in public capital markets through Chess Depository Interests liste...
Imricor to Release 315,900 Shares from Voluntary Escrow Under ASX Rules
May 8, 2026
Imricor Medical Systems will release 315,900 Class A common shares, including equivalent CHESS Depositary Interests, from voluntary escrow on 16 May 2026 in line with ASX Listing Rule 3.10A. The company also reiterates that its CDIs, issued under ...
Imricor marks pivotal year as it builds MR-guided cardiac ablation platform
May 8, 2026
Imricor Medical Systems used its latest chair’s address to underline progress in shifting from development to execution as it seeks to establish interventional MR as a new standard of care in electrophysiology. The company highlighted advanc...
Imricor Outlines Equity Raising Plan to Support iCMR Commercial Expansion
May 4, 2026
Imricor Medical Systems has released an equity raising presentation outlining a proposed capital raising via a placement of CHESS Depositary Interests to sophisticated and professional investors. The document positions the raise as part of the com...
Imricor Plans Major CDI Placement to Raise Capital on ASX
May 3, 2026
Imricor Medical Systems has notified the ASX of a proposed placement involving the issue of up to 32,432,433 CHESS Depositary Interests, each representing one share, under the code IMR CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB. The new securities...
Imricor raises A$60m to accelerate global rollout of interventional MR platform
May 3, 2026
Imricor Medical Systems has secured firm commitments to raise A$60 million through a placement of 32.4 million new CHESS Depositary Interests to institutional and sophisticated investors at A$1.85 per CDI, a modest discount to recent trading price...
Imricor Seeks ASX Trading Halt Ahead of Capital Raising Announcement
Apr 30, 2026
Imricor Medical Systems has requested an immediate trading halt of its CHESS Depositary Interests on the ASX, as it prepares a material announcement regarding a proposed capital raising. The halt, granted under ASX Listing Rule 17.1, will remain i...
Imricor Builds U.S. Momentum as MRI-Guided EP Platform Enters Commercial Acceleration
Apr 27, 2026
Imricor reported a strong start to 2026, entering the year with key U.S. FDA clearances for its NorthStar navigation system and Vision-MR diagnostic catheter, while also filing for 510(k) clearance of its Advantage-MR System. The company expanded ...
Imricor Amends Form 10 as It Tightens Compliance on U.S. Securities Rules
Apr 26, 2026
Imricor Medical Systems has filed an amendment to its Form 10 Registration Statement with the U.S. Securities and Exchange Commission, clarifying minor points identified during the regulator’s standard review and reiterating that the filing ...
Imricor Issues 310,000 Unquoted Options Under Employee Incentive Scheme
Apr 16, 2026
Imricor Medical Systems Inc. has notified the market of the issue of 310,000 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective from April 1, 2026. The options, which will not be quoted o...
Imricor Targets U.S. Pediatric Market With FDA Bid for NorthStar Expansion
Apr 7, 2026
Imricor Medical Systems has submitted its NorthStar Mapping System to the U.S. Food and Drug Administration for a pediatric label expansion using the Special 510(k) pathway, building on its recent clearance for adult use. The move is central to th...
Imricor Sets Fully Virtual 2026 AGM as It Advances MRI-Guided Interventional Focus
Mar 26, 2026
Imricor Medical Systems, Inc., an ASX-listed medtech company, specializes in solutions that allow interventional procedures to be carried out under real-time MRI guidance rather than x-ray fluoroscopy, targeting improved safety, imaging quality, a...
Imricor lodges updated ASX corporate governance statement for 2025
Mar 26, 2026
Imricor Medical Systems has lodged its latest corporate governance statement with the ASX for the financial year ended 31 December 2025, confirming the document is current as of 27 March 2026 and approved by the board. The filing, accompanied by a...
Imricor Registers With U.S. SEC After Exceeding Shareholder Thresholds
Mar 18, 2026
Imricor Medical Systems has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission after surpassing shareholder thresholds that trigger mandatory registration under U.S. securities laws. The company stressed that t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.